PROPEL研究:药代动力学指导的rurioctocog alfa pegol预防治疗在血友病A中的3期结果
PROPEL是一项3期随机试验,比较靶向FVIII谷浓度1%–3%与8%–12%的PK指导预防治疗。两组安全性可接受,未见新安全信号。
要点
- 靶向FVIII谷浓度8%–12%可提高零出血患者比例。
- 两组均未出现死亡、严重血栓事件或因不良事件停药。
核心结论
- PK指导的rurioctocog alfa pegol预防治疗在靶向FVIII谷浓度1%–3%和8%–12%时均可实现且有效。
- 抬高FVIII谷浓度至8%–12%可增加零出血患者比例,并强调个体化治疗的重要性。
研究设计与样本
- 3期随机试验,纳入12–65岁重度血友病A患者,年化出血率≥2且既往接受过FVIII治疗。
- 随机接受12个月PK指导的rurioctocog alfa pegol预防治疗,靶向FVIII谷浓度1%–3%(参考组)或8%–12%(抬高组),前6个月为治疗调整期。
- 主要终点为后6个月无出血,采用多重插补分析全分析集(FAS)。
主要发现
- 不良事件发生于70/115(60.9%)患者,严重不良事件发生于7/115(6%)患者,包括8%–12%组1例治疗相关严重不良事件(短暂抗FVIII抑制物)。
- 无死亡、严重血栓事件或不良事件相关停药。
临床怎么用
- PK指导的预防治疗可根据患者情况选择不同FVIII谷浓度目标,抬高至8%–12%可能使更多患者达到零出血。
- 治疗期间需监测不良事件,包括抗FVIII抑制物形成。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rurioctocog alfa pegol prophylaxis targeting factor VIII (FVIII) troughs ≥1% has shown to be efficacious with an acceptable safety profile in people with hemophilia A (PwHA). The PROPEL trial compared safety and efficacy of 2 target FVIII troughs in PwHA aged 12 to 65 years, with severe disease, annualized bleeding rate ≥2, and previous FVIII treatment. PwHA were randomized to 12 months' pharmacokinetic (PK)-guided rurioctocog alfa pegol prophylaxis targeting FVIII troughs of 1% to 3% (reference arm) or 8% to 12% (elevated arm); first 6 months was treatment-adjustment period. The primary endpoint was absence of bleeds during the second 6 months, analyzed using multiple imputations (full analysis set [FAS]). In the 1% to 3% and 8% to 12% arms, respectively, point estimates (95% confidence interval) of proportions of PwHA with zero total bleeds were 42% (29% to 55%) and 62% (49% to 75%) in FAS (N = 115; P = .055) and 40% (27% to 55%) and 67% (52% to 81%) in per-protocol analysis set (N = 95; P = .015). Dosing frequency and consumption varied in each arm. Adverse events (AEs) occurred in 70/115 (60.9%) PwHA; serious AEs in 7/115 (6%) PwHA, including 1 treatment-related in 8% to 12% arm (transient anti-FVIII inhibitor). There were no deaths, serious thrombotic events, or AE-related discontinuations. PK-guided prophylaxis was achievable and efficacious in both arms. No new safety signals were observed in the 8% to 12% arm. These results demonstrate elevated FVIII troughs can increase the proportion of PwHA with zero bleeds and emphasize the importance of personalized treatment. This trial was registered at www.clinicaltrials.gov as #NCT02585960.
引用
- Klamroth R, Windyga J, Radulescu V, et al. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood. 2021. PMID: 33150384. doi:10.1182/blood.2020005673
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。